{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Health&Fitness", "lead_paragraph": "No one disputes that colonoscopies save lives. But recent research has prompted concern that in rare instances certain popular bowel-cleansing preparations that patients gulp down the day before a procedure can severely damage the kidneys. The products are oral preparations made with sodium phosphate and they include Visicol tablets, sold by prescription, and over-the-counter solutions like Fleet-Phosphosoda and store-brand versions that contain the same active ingredients.", "headline": {"main": "Danger to Kidneys May Lurk in Some Preparations for Colonoscopies", "kicker": "THE CONSUMER"}, "abstract": "Columbia College of Physicians and Surgeons reports 21 cases of acute kidney failure linked to use of sodium phosphate-based bowel-cleansers used before colonoscopy; research is published in Journal of the American Society of Nephrology; does not suggest skipping colonoscopy, but sets more comprehensive list of people who should consider different type of prep for test and avoid sodium phosphates; research described (M)", "print_page": "5", "word_count": 1230, "_id": "4fd2aa048eb7c8105d895c11", "snippet": "A new study has linked oral cleansers using sodium phosphate to acute kidney failure.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/12/27/health/27cons.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY"}, {"name": "organizations", "value": "COLUMBIA COLLEGE OF PHYSICIANS AND SURGEONS"}, {"name": "subject", "value": "COLON"}, {"name": "subject", "value": "SODIUM PHOSPHATE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "KIDNEYS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Deborah", "rank": 1, "lastname": "FRANKLIN"}], "original": "By DEBORAH FRANKLIN"}, "document_type": "article", "pub_date": "2005-12-27T00:00:00Z", "section_name": "Health"}, {"type_of_material": "Series", "blog": [], "news_desk": "Health&Fitness", "lead_paragraph": "Jay Weinstein found out that he had chronic myelogenous leukemia in 1996, two weeks before his marriage. He was 36 years old, a New York City firefighter, and he thought his health was great.", "headline": {"main": "Slowly, Cancer Genes Tender Their Secrets", "kicker": "Preventing Cancer"}, "abstract": "Researchers describe continuing efforts to determine genetic changes and mutations that generate various types of cancers; Dr Brian Druker, Howard Hughes Medical Institute investigator at Oregon Health and Science University Cancer Institute, describes success treating patients with drug Gleevec, which acts as molecular razor to cut out cancer cells, rather than with traditional chemotherapy or radiation; Dr Bert Vogelstein of John Hopkins University leads research that has identified mutations that normal cell goes through to become cancer cell; other research discussed; photos (L)", "print_page": "1", "word_count": 2149, "_id": "4fd24e768eb7c8105d7f0292", "snippet": "Scientists are now finding that untangling the genetics of cancer is not impossible and are basing new treatments on their findings.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/12/27/health/27canc.html", "multimedia": [{"credit": "The Times's Gina Kolata reports on the case of retired firefighter Jay Weinstein, whose life was saved when a new cancer drug worked to fight his leukemia. (Producer: Craig Duff)", "url": "http://nytimes.feedroom.com/?fr_story=bcf646df732c03328d717c7ff0039da3ed61f4ab", "pay": "n", "rank": "1", "height": 700, "width": 820, "legacy": {"MultimediaPopupHeight1": "700", "MultimediaType1": "External", "MultimediaPopupWidth1": "820", "MultimediaUrl1": "http://nytimes.feedroom.com/?fr_story=bcf646df732c03328d717c7ff0039da3ed61f4ab", "MultimediaPay1": "n", "MultimediaSummary1": "The Times's Gina Kolata reports on the case of retired firefighter Jay Weinstein, whose life was saved when a new cancer drug worked to fight his leukemia. (Producer: Craig Duff)", "MultimediaHeadline1": "Next Generation Cancer Drugs", "MultimediaCol1": "VIDEO"}, "caption": "Next Generation Cancer Drugs", "type": "External", "col": "VIDEO"}, {"url": "images/2005/12/27/science/27canc75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2005/12/27/science/27canc75.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "persons", "value": "VOGELSTEIN, BERT"}, {"name": "persons", "value": "DRUKER, BRIAN J"}, {"name": "organizations", "value": "OREGON HEALTH AND SCIENCE UNIVERSITY"}, {"name": "organizations", "value": "JOHNS HOPKINS UNIVERSITY"}, {"name": "organizations", "value": "HUGHES, HOWARD, MEDICAL INSTITUTE"}, {"name": "subject", "value": "RADIATION"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "GLEEVEC (DRUG)"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "CELLS (BIOLOGICAL)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gina", "rank": 1, "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2005-12-27T00:00:00Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Westchester Weekly Desk", "lead_paragraph": "IN response to widespread confusion about Medicare's new Prescription Drug Plan for the elderly, which is to take effect Jan. 1, Westchester's Department of Senior Programs and Services has opened information centers throughout the county. ''This thing can drive you insane,'' Jean Grant, 79, said last week after her meeting at a county information center in Mount Vernon. ''But finally, after a two-hour appointment, I'm beginning to see the light.''", "headline": {"main": "How to Sort Through the Maze of New Drug Plans", "kicker": "BENEFITS"}, "abstract": null, "print_page": "4", "word_count": 842, "_id": "4fd2aa038eb7c8105d895bd6", "snippet": "IN response to widespread confusion about Medicare's new Prescription Drug Plan for the elderly, which is to take effect Jan. 1, Westchester's Department of Senior Programs and Services has opened information centers throughout the county.     ''This...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9F0DE0D81430F936A15751C1A9639C8B63", "multimedia": [], "subsection_name": null, "keywords": [], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Elsa", "rank": 1, "lastname": "BRENNER"}], "original": "By ELSA BRENNER"}, "document_type": "article", "pub_date": "2005-12-25T00:00:00Z", "section_name": "New York and Region"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "For years, the biotechnology giant Amgen has wielded a near monopoly over its industry's most lucrative franchise, the anemia drugs on which hundreds of thousands of American kidney and cancer patients and their insurers spend billions of dollars each year. But now, Amgen's money machine is coming under attack. A host of companies -- ranging from the Swiss giant Roche to Silicon Valley start-ups -- are developing anemia drugs to compete against Epogen and Aranesp, the blockbusters that will account for nearly half of Amgen's expected $12 billion in revenues this year.", "headline": {"main": "A Biotech Battle Royal; Rivals Laying Siege to Amgen's Near Monopoly in Anemia Drugs"}, "abstract": "Host of companies arfe developing anemia drugs to compete against Amgen's Epogen and Aranesp, which will acount for nearly half of Amgen's expected $12 billion in revenues this year; Amgen filed patent infringement suit against Roche last month; Amgen's annual earnings growth over next five years could be cut by more than 50 percent if Roche were to capture half American market; some Amgen critics say that while its anemia drugs have helped people, its near monopoly is last much longer than patent law was meant to allow; company has sold about $22 billion worth of Epogen since its approval in 1989 and $7 billion worth of Aranesp since 2001; chart; photo (M)", "print_page": "1", "word_count": 1800, "_id": "4fd24e758eb7c8105d7f01d2", "snippet": "A host of companies - ranging from the Swiss giant Roche to Silicon Valley start-ups - are gearing up to compete against Amgen's near monopoly in anemia drugs.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/12/23/business/23epo.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "ROCHE HOLDING LTD"}, {"name": "organizations", "value": "AMGEN INCORPORATED"}, {"name": "organizations", "value": "AMGEN INC"}, {"name": "subject", "value": "ANTITRUST ACTIONS AND LAWS"}, {"name": "subject", "value": "EPOGEN (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARANESP (DRUG)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "INVENTIONS AND PATENTS"}, {"name": "subject", "value": "BIOTECHNOLOGY"}, {"name": "subject", "value": "ANEMIA"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2005-12-23T00:00:00Z", "section_name": "Technology; Health; Business"}, {"type_of_material": "Series", "blog": [], "news_desk": "Metropolitan Desk", "lead_paragraph": "In the last three years, Chemung County has raised taxes and laid off workers. It has closed libraries and cut arts programs. Now, to help balance the budget, it will more than double the capacity of the landfill that everyone hoped would soon close. This thinly populated rural county is one of dozens that have been driven to financial desperation by the rapidly rising cost of Medicaid, the government health plan for the poor.", "headline": {"main": "As Medicaid Rolls Grow, Costs Take a Local Toll", "kicker": "Program Disorder"}, "abstract": "Sixth article in series Program Disorder, on cost of New York's Medicaid program, state's biggest expense, and its impact on local governments that bear large share of costs; New York, with country's largest Medicaid budget, is only state that requires local governments to pay large share of cost; this year, counties and New York City will pay $6.6 billion, 15 percent of state's Medicaid budget; crisis is most serious in counties upstate, which lack broad tax base but have growing Medicaid population; counties also bear their share of billions of Medicaid dollars lost each year to fraud and waste, increasing frustration of local officials critical of state for inadequate monitoring of its spending; to pay Medicaid bills, counties are raising property taxes and cutting jobs and services; New York State Legislature, under pressure from county officials, this year passed cap on local Medicaid costs; but costs will continue to be significant burden for counties for years to come; photos; map (L)", "print_page": "1", "word_count": 2908, "_id": "4fd24e288eb7c8105d7efc14", "snippet": "Dozens of rural counties in New York have been driven to financial desperation by the rapidly rising cost of Medicaid.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/12/23/nyregion/nyregionspecial4/23medicaid.html", "multimedia": [{"url": "images/2005/12/23/nyregion/23medi75.1.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2005/12/23/nyregion/23medi75.1.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "persons", "value": "PEREZ-PENA, RICHARD"}, {"name": "glocations", "value": "NEW YORK STATE"}, {"name": "glocations", "value": "NEW YORK CITY"}, {"name": "subject", "value": "FRAUDS AND SWINDLING"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "SURVEYS AND SERIES"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "MEDICAID"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LOCAL GOVERNMENT"}, {"name": "subject", "value": "BUDGETS AND BUDGETING"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Richard", "rank": 1, "lastname": "P\u00c9REZ-PE\u00d1A"}, {"organization": "", "role": "reported", "firstname": "Michael", "rank": 2, "lastname": "LUO"}], "original": "By RICHARD P\u00c9REZ-PE\u00d1A and MICHAEL LUO"}, "document_type": "article", "pub_date": "2005-12-23T00:00:00Z", "section_name": "Front Page; Health; New York and Region"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Amgen's patents on Epogen and Aranesp are not the only barriers to competing drugs in this country. The federal government still needs to figure out how to approve generic versions of biotechnology medicines. When patents expire on conventional drugs that are made chemically, as most pills sold by big pharmaceutical companies are, generic makers can quickly win approval of copycat versions. All they need to do is demonstrate that their drugs are chemically identical to the branded products and act the same way in the body. But those rules do not cover drugs made in living cells, like the EPO protein at the core of Amgen's anemia drug.", "headline": {"main": "Approval Process Still Not Set"}, "abstract": null, "print_page": "6", "word_count": 334, "_id": "4fd24e288eb7c8105d7efc13", "snippet": "The federal government still needs to figure out how to approve generic versions of biotechnology medicines.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/12/23/business/23generic.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "BIOTECHNOLOGY"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2005-12-23T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 6, "offset": 0, "time": 51}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}